←MRKMerck & Co.Our view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Merck is the maker of Keytruda

Keytruda

the top-selling cancer drug

Gardasil

a vaccine against HPV

Animal health

medicines for pets and farms

Merck is a large drug maker. Keytruda helps the immune system attack cancer and is approved for over 45 uses in America; hospitals buy it, paid by insurers and Medicare.

The company · 2 · What exactly does it sell?

Keytruda is half of sales

Each $1 of sales, second quarter of 2026
50%26%11%7%4%3%
KeytrudaOther medicinesAnimal healthGardasil vaccineWinrevairDiabetes pills

Everything else Merck sells together is the other half.

The company · 3 · How does it make money?

Patented drugs, paid by insurers and Medicare

$67.4Bsales in the past year
$14.7Bfree cash in the past year
+1.3%sales growth in 2025

A patented drug earns a high profit until copies arrive, then sales fall fast.

Is it a good business? · 4 · What gives it an edge?

The law kept rivals out; now only patents

September 2026

the 12-year bar on copies ended

2028

Keytruda's main patent ends

2043

patent on the injected version

Merck's plan is to move patients to Qlex, the same medicine injected under the skin in minutes.

Is it a good business? · 5 · What is the catch?

Three kinds of attack are lined up

Amgentesting cheaper copies for 2028
Summita rival drug tested head to head
Halozymepatents on an injection ingredient

Listed rivals: BMY · AMGN · ALVO · RDY · CIPLA.NS · SMMT · 9926.HK · HALO

Bristol's Opdivo is the older rival, and copies are already in trials.

Is it a good business? · 6 · What does its record show?

Sales rose, growth has slowed

Sales, $B
48.7
59.3
60.1
64.2
65.0
67.4
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$48.7B → $67.4Bsales, 2021 to the past year
Growth+1.3%sales growth in 2025
Cash$8.67B → $14.7Bfree cash

Making and selling got cheaper per dollar; research costs swing with the deals charged to it.

Is it a good business? · 7 · How much room is there to grow?

Half of US cancer patients could qualify

About 2.1 millionAmericans diagnosed with cancer, 2026
About $8,900of US Keytruda sales per new case
20 millionnew cases a year elsewhere

Nobody has measured eligibility since 2018, and the rest of the world pays far less.

Is it a good business? · 8 · Who is in charge?

A former finance chief runs it

2021Robert Davis became chief executive
2014when he joined as finance chief
2025sales missed the board's target

The shares lagged rival drug makers over three years.

The story right now · 9 · What happens when a patent ends?

Copies arrive and prices collapse

2028Keytruda's main patent ends
49%of Merck's 2025 sales came from Keytruda
Early 2027Medicare may set its price

When a drug's patent ends, cheaper copies can be sold and its sales usually fall steeply. Drug makers race to replace that income before the date arrives.

The story right now · 10 · How can Merck soften the cliff?

A new patented version keeps patients

  1. Keytruda's patent ends2028.
  2. Qlex, injected in minutesPatented to 2043.
  3. Patients switch over$830M a quarter already.
  4. Patent cases in courtUnresolved.

A patent holder has already stopped Qlex in part of Europe, and a German appeal is heard on 19 November.

The story right now · 11 · What changed lately?

Sales up 5%, the injected version climbing

$830MQlex sales, from $463M
$694MWinrevair sales, nearly doubled
About $550Mof growth from buying timing
$66.8B to $67.3Braised sales forecast

Solid quarter

Summit's head-to-head lung-cancer result is due by the end of 2026.

The story right now · 12 · What is everyone arguing about?

A shallow dip, or a hard cliff?

Many investors think

A shallow dip, carried by many new medicines

We think

Possible, but the injected version is in court

Against us: three late-stage trial wins this year and a cholesterol pill approved.

The price and our view · 13 · What is a share worth?

The price pays for a smooth passage past the patent

$115what we think a share is worth
$115our value
Attractive
below $91.83
Neutral
Unattractive
above $138
$65.17gloomy: growth halves, less kept per $1
$115our estimate: experts' path, then slowing
$143sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · How could we be wrong?

Patent cases and copies

Qlex blocked in courtBiggest

Patent cases open.

Copies from 2028Watch

Amgen and others.

Medicare price-settingShowing now

Expected early 2027.

Replacement salesUnknown

Most not on sale.

Summit's rival drug could also beat Keytruda in lung cancer.

The price and our view · 15 · How will we know?

19 November starts the test run

German court rules for QlexGood sign
Summit's drug fails to beat KeytrudaGood sign
Medicare picks KeytrudaBad sign
FEB 202710

Fourth-quarter and full-year 2026 results, 10 February. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 16 · So, what do we think?

Keytruda pays, but its patent clock runs out

$115our value
Attractive
below $91.83
Neutral
Unattractive
above $138

UnattractiveMedium conviction

Keytruda is very profitable, but half of sales rests on it, its patent ends in 2028 and sales barely grew for three years. The price sits above even our sunny future.

↑ ↓ to move · C for contents